Keep checking back, because we will keep updating this chart based on the lasts research findings and FDA Approvals
Taking the medication with food can significantly reduce its effectiveness
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis KEY MARKET PLAYERS Novo Nordisk A/S (Denmark) Eli Lilly and Company (US) Sanofi (France) Hansoh Pharmaceutical Group Co., Ltd
The goal is to identify and reduce foods that trigger symptoms whilst maintaining adequate nutrition for weight management
(Source: Long-term GLP-1 safety review, June 2026) There Is No Evidence Supporting a Hard Time Limit on Treatment A frequent patient concern is that GLP-1s cannot be safe indefinitely
That number is not just large in absolute terms, it is the largest weight-loss signal ever reported in a randomized Phase 3 trial of a GLP-1-class compound, and it arrived with additional secondary findings that reframe what "GLP-1 therapy" could eventually mean: a 75.8% reduction in osteoarthritis pain, a roughly 20% drop in LDL cholesterol, and a 72% reversal rate of prediabetes to normoglycemia in the affected subpopulation
